CD4 and myeloid sarcoma: The aim of the current study is to evaluate miR-141 and miR-200a expression in CD4+ T cells of relapsing versus remitting phase of MS patients; through which we tried to find their possible role in differentiation or suppression of Th17 and/or Treg cells by assessing the correlation between them and the percentage of these cells in different phases of MS.